Post-chemotherapy serum anti-müllerian hormone level predicts ovarian function recovery
Abstract
In the era of precision medicine, the prediction of ovarian function recovery from chemotherapy-induced amenorrhoea using feasible biological markers may be helpful to optimise the treatment strategy for young patients with hormone receptor-positive breast cancer. The purpose of this study was to investigate the accuracy of post-chemotherapy biological markers for predicting the recovery of ovarian function in breast cancer patients of the ASTRRA trial, with chemotherapy-induced amenorrhoea. Using data of 82 participants from a single institution in the ASTRRA trial, the post-chemotherapy serum levels of the anti-müllerian hormone (AMH), estradiol, inhibin B, and other clinical factors associated with chemotherapy-induced amenorrhoea were evaluated. Recovery of ovarian function was defined by the resumption of menstruation manifested by vaginal bleeding. Fifty-two patients regained menstruation within 55 months after enrolment. In univariate analysis, <40 years of age (p=0.009), estradiol ≥37 pg/mL (p=0.003), or AMH ≥800 pg/mL (p=0.026) were associated with recovery of menstruation. On multivariate analysis, estradiol (hazard ratio: 3.171, 95% CI: 1.306-7.699, p=0.011) and AMH (hazard ratio: 2.853, 95% CI: 1.011-8.046, p=0.048)...Continue Reading
References
Dynamics and mechanisms of chemotherapy-induced ovarian follicular depletion in women of fertile age
Predicting Ovarian Activity in Women Affected by Early Breast Cancer: A Meta-Analysis-Based Nomogram
Citations
Methods Mentioned
Software Mentioned
Related Concepts
Related Feeds
Antiphospholipid Syndrome
Antiphospholipid syndrome or antiphospholipid antibody syndrome (APS or APLS), is an autoimmune, hypercoagulable state caused by the presence of antibodies directed against phospholipids.